menu
    • menu
    [{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"CBP-4888","moa":"sFlt1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comanche Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Series B Financing","leadProduct":"CBP-4888","moa":"sFlt1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comanche Biopharma \/ Google Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Google Ventures"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"CBP-4888","moa":"||sFlt1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comanche Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"CBP-4888","moa":"sFlt1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comanche Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Comanche Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"CBP-4888","moa":"sFlt1","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Comanche Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Comanche Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Comanche Biopharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Comanche Biopharma

    Menu

    Comanche Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Comanche Biopharma

                            United Kingdom arrow
                            RDD 2025
                            Not Confirmed

                            Comanche Biopharma

                            United Kingdom arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBP-4888

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comanche Wins EMA Orphan Status for CBP-4888 in Preterm Preeclampsia

                            Details : CBP-4888 is designed to selectively downregulate the disease-causing overexpression of the sFlt-1 protein in patients with sFlt-1-mediated preterm preeclampsia.

                            Product Name : CBP-4888

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            April 08, 2025

                            Lead Product(s) : CBP-4888

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Comanche Biopharma

                            United Kingdom arrow
                            RDD 2025
                            Not Confirmed

                            Comanche Biopharma

                            United Kingdom arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBP-4888

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comanche Gets UK ILAP Innovation Passport for CBP-4888 in Preterm Preeclampsia

                            Details : CBP-4888 leverages the precise targeting ability of siRNAs to downregulate sFlt1 in the placenta, a key pathogenic mediator of preeclampsia.

                            Product Name : CBP-4888

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            January 30, 2025

                            Lead Product(s) : CBP-4888

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Comanche Biopharma

                            United Kingdom arrow
                            RDD 2025
                            Not Confirmed

                            Comanche Biopharma

                            United Kingdom arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBP-4888

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Google Ventures

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Comanche Biopharma Closes $75 Million Series B Financing for Preeclampsia Treatment

                            Details : Comanche will initiate a clinical study of CBP-4888, a fixed-dose combination of two siRNA oligonucleotides targeting soluble fms-like tyrosine kinase–1 (sFLT1) in preeclamptic patients.

                            Product Name : CBP-4888

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            January 17, 2024

                            Lead Product(s) : CBP-4888

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Google Ventures

                            Deal Size : $75.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Comanche Biopharma

                            United Kingdom arrow
                            RDD 2025
                            Not Confirmed

                            Comanche Biopharma

                            United Kingdom arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBP-4888,siRNA-2519

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comanche Biopharma Receives US FDA Fast Track Designation for CBP-4888 for the Treatment of sFlt-1 Mediated Pr...

                            Details : CBP-4888 is a fixed-dose combination of siRNA-2283 and siRNA-2519 targeting two soluble fms-like tyrosine kinase–1 (sFLT1) mRNA isoforms, which is investigated for the treatment of sFlt-1 mediated pre-term preeclampsia.

                            Product Name : CBP-4888

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            August 23, 2023

                            Lead Product(s) : CBP-4888,siRNA-2519

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Comanche Biopharma

                            United Kingdom arrow
                            RDD 2025
                            Not Confirmed

                            Comanche Biopharma

                            United Kingdom arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CBP-4888

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP-4888, an siRN...

                            Details : CBP-4888 is a fixed-dose combination of two chemically-synthesized, lipid-conjugated siRNAs duplex oligonucleotides (siRNA-2283 and siRNA-2519) targeting and decreasing the production of soluble fms-like tyrosine kinase-1 in the placenta, as a treament f...

                            Product Name : CBP-4888

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            March 30, 2023

                            Lead Product(s) : CBP-4888

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth